838
Views
0
CrossRef citations to date
0
Altmetric
Infectious Diseases

Clinical characteristics of tracheobronchial Talaromyces marneffei infection in non-HIV-infected patients in South China

, , , , , , , & show all
Article: 2276310 | Received 30 Oct 2022, Accepted 22 Oct 2023, Published online: 15 Nov 2023

References

  • Qiu Y, Zhang JQ, Pan ML, et al. Determinants of prognosis in Talaromyces marneffei infections with respiratory system lesions. Chin Med J. 2019;132(16):1–15. doi: 10.1097/CM9.0000000000000345.
  • Qiu Y, Zhang J, Liu G, et al. A case of Penicillium marneffei infection involving the main tracheal structure. BMC Infect Dis. 2014;14(1):242. doi: 10.1186/1471-2334-14-242.
  • Zeng W, Qiu Y, Tang S, et al. Characterization of anti-Interferon-γ antibodies in HIV-negative patients infected with disseminated Talaromyces marneffei and cryptococcosis. Open Forum Infect Dis. 2019;6(10):ofz208. Oct 11
  • Vanittanakom N, Cooper CR, Fisher MC, et al. Penicillium marneffei infection and recent advances in the epidemiology and molecular biology aspects. Clin Microbiol Rev. 2006;19(1):95–110. doi: 10.1128/CMR.19.1.95-110.2006.
  • Qiu Y, Feng X, Zhang J, et al. Immunodeficiency disease spectrum in HIV-negative individuals with talaromycosis. J Clin Immunol. 2021;41(1):221–223. doi: 10.1007/s10875-020-00869-5.
  • Chan JF, Lau SK, Woo PC, et al. Talaromyces (penicillium) marneffei infection in non-HIV-infected patients. Emerg Microbes Infect. 2016;5(3):e19–9. doi: 10.1038/emi.2016.18.
  • Chi CY, Lin CH, Ku CL, et al. Clinical manifestations, course, and outcome of patients with neutralizing anti-interferon-γ autoantibodies and disseminated nontuberculous mycobacterial infections. Medicine. 2016;95(25):e3927. Jundoi: 10.1097/MD.0000000000003927.
  • Guo J, Ning XQ, Cao CW, et al. Anti-IFN-γ autoantibodies underlie disseminated Talaromyces marneffei infections. J Exp Med. 2020;217(12):e20190502. Dec 7
  • Tang BS, Chan JF, Yuen KY, et al. Disseminated penicilliosis, recurrent bacteremic nontyphoidal salmonellosis, and burkholderiosis associated with acquired immunodeficiency due to autoantibody against gamma interferon. Clin Vaccine Immunol. 2010;17(7):1132–1138. Juldoi: 10.1128/CVI.00053-10.
  • Simner PJ, Miller S, Carroll KC. Understanding the promises and hurdles of metagenomic next-generation sequencing as a diagnostic tool for infectious diseases. Clin Infect Dis. 2018;66(5):778–788. doi: 10.1093/cid/cix881.
  • Lei HL, Li LH, Chen WS, et al. Susceptibility profile of echinocandins, azoles and amphotericin B against yeast phase of Talaromyces marneffei isolated from HIV-infected patients in Guangdong, China. Eur J Clin Microbiol Infect Dis. 2018;37(6):1099–1102. doi: 10.1007/s10096-018-3222-x.
  • Kaplan JE, Benson C, Masur H, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58(RR-4):1–207.
  • Huang W, Li T, Zhou C, et al. Voriconazole Versus Amphotericin B as Induction Therapy for Talaromycosis in HIV/AIDS Patients: A Retrospective Study. Mycopathologia. 2021 May;186(2):269-276. doi: 10.1007/s11046-021-00533-5.
  • Rijnders BJ, Cornelissen JJ, de Marie S, et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis. 2008;46(9):1401–1408. doi: 10.1086/586739.